Pharmacological Treatment of Fibromyalgia Syndrome: A Practice-Based Review
Authors:
- Valeria GiorgiVGValeria Giorgi
- Piercarlo Sarzi-PuttiniPSPiercarlo Sarzi-Puttini
- Greta PellegrinoGPGreta Pellegrino
- Silvia SirottiSSSilvia Sirotti
- Fabiola AtzeniFAFabiola Atzeni
- Alessandra AlciatiAAAlessandra Alciati
- Riccardo TortaRTRiccardo Torta
- Giustino VarrassiGiustino Varrassi
- Diego FornasariDFDiego Fornasari
- Stefano CoaccioliSCStefano Coaccioli
- Sara Francesca BongiovanniSBSara Francesca Bongiovanni
Open Access
- 23 July 2024
- journal article
- review article
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 28 (12) , 1349-1363
Abstract
Purpose of Review: Fibromyalgia Syndrome (FMS) is a complex chronic pain condition characterized by widespread musculoskeletal pain and numerous other debilitating symptoms. The purpose of this review is to provide a comprehensive overview, based on everyday clinical practice, of the drugs presently employed in the treatment of FMS. Recent Findings: The treatment of FMS is based on a multimodal approach, with pharmacologic treatment being an essential pillar. The drugs used include tricyclic antidepressants, serotonin and noradrenaline reuptake inhibitors, other antidepressants, anticonvulsants, myorelaxants, and analgesics. The effectiveness of these medications varies, and the choice of drug often depends on the specific symptoms presented by the patient. Many drugs tend to either address only some domains of the complex FMS symptomatology or have a limited effect on pain. Summary: Each treatment option comes with potential side effects and risks that necessitate careful consideration. It may be beneficial to divide patients into clinical subpopulations, such as FMS with comorbid depression, for more effective treatment. Despite the complexities and challenges, the pharmacological treatment remains a crucial part for the management of FMS. This review aims to guide clinicians in prescribing pharmacological treatment to individuals with FMS.Keywords
This publication has 109 references indexed in Scilit:
- The diverse CB1and CB2receptor pharmacology of three plant cannabinoids: Δ9‐tetrahydrocannabinol, cannabidiol and Δ9‐tetrahydrocannabivarinBritish Journal of Pharmacology, 2008
- Decreased Central μ-Opioid Receptor Availability in FibromyalgiaThe Journal of Neuroscience, 2007
- An open-label study of quetiapine in the treatment of fibromyalgiaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2006
- Decreased Pain and Improved Quality of Life in Fibromyalgia Patients Treated with Olanzapine, an Atypical NeurolepticPain Practice, 2006
- Evaluation of Reboxetine, a Noradrenergic Antidepressant, for the Treatment of Fibromyalgia and Chronic Low Back PainPsychosomatics, 2005
- Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2005
- Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapineProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2005
- Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled studyThe American Journal of Medicine, 2003
- GABA and GABA Receptors in the Central Nervous System and Other Organs2002
- Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patientsPain, 2000